Determination of plasma and cerebrospinal fluid drug concentrations during high-dose cytosine arabinoside treatment

谢晓恬,李本尚,李莉,廖雪莲,石苇

DOI: https://doi.org/10.3969/j.issn.0253-9934.2005.03.013

2005-01-01

Abstract:Objective To determine the concentrations of cytosine arabinoside (Ara-C) in plasma and cerebrospinal fluid (CSF) in childhood lymphoblastic leukemia (ALL) and aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose Ara-C (HD-AraC) and standard dose Ara-C(SD-AraC), and also to study the drug metabolism and the advantage of HD-AraC in the treatment of childhood hematologic malignancies.Methods A HPLC method was set up in order to determine the drug levels in plasma and CSF. Plasma and CSF samples were collected from the patients who were receiving HD-AraC (2.0 g/m 2) infusion. Results The mean plasma peak levels of Ara-C and Ara-U were (49.94±26.03) μmol/L and (162.10±108.06) μmol/L which were about fifty times and twenty five times as high as the levels (1.07 μmol/L and 6.81 μmol/L) of standard dose Ara-C. The mean CSF levels of Ara-C and Ara-U were (5.93±4.01) μmol/L and (20.98±10.41) μmol/L respectively. The results showed that the mean peak level of Ara-U was much higher than that of Ara-C, and there were significant individual difference in the peak drug levels of plasma and CSF.Conclusion The plasma drug levels can be significantly elevated resulting in a relative higher level in the CSF by using HD-AraC, which may be the pharmacological basis of good outcomes obtained in clinical treatment. Considering the presence of individual difference among the patients, further study of drug metabolism of Ara-C might provide the basis for individual treatment in the future.